Co-trimoxazole

Co-trimoxazole
Combination of
Trimethoprim	Dihydrofolate reductase inhibitor (20%)
Sulfamethoxazole	Sulfonamide antibiotic (80%)
Identifiers
CAS number	8064-90-2
ATC code	J01EE01
PubChem	358641
Therapeutic considerations
Pregnancy cat.	C(AU) C(US)
Legal status	℞-only(US)
Routes	Oral

WikiDoc Resources for Co-trimoxazole
Articles
Most recent articles on Co-trimoxazole Most cited articles on Co-trimoxazole Review articles on Co-trimoxazole Articles on Co-trimoxazole in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Co-trimoxazole Images of Co-trimoxazole Photos of Co-trimoxazole Podcasts & MP3s on Co-trimoxazole Videos on Co-trimoxazole
Evidence Based Medicine
Cochrane Collaboration on Co-trimoxazole Bandolier on Co-trimoxazole TRIP on Co-trimoxazole
Clinical Trials
Ongoing Trials on Co-trimoxazole at Clinical Trials.gov Trial results on Co-trimoxazole Clinical Trials on Co-trimoxazole at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Co-trimoxazole NICE Guidance on Co-trimoxazole NHS PRODIGY Guidance FDA on Co-trimoxazole CDC on Co-trimoxazole
Books
Books on Co-trimoxazole
News
Co-trimoxazole in the news Be alerted to news on Co-trimoxazole News trends on Co-trimoxazole
Commentary
Blogs on Co-trimoxazole
Definitions
Definitions of Co-trimoxazole
Patient Resources / Community
Patient resources on Co-trimoxazole Discussion groups on Co-trimoxazole Patient Handouts on Co-trimoxazole Directions to Hospitals Treating Co-trimoxazole Risk calculators and risk factors for Co-trimoxazole
Healthcare Provider Resources
Symptoms of Co-trimoxazole Causes & Risk Factors for Co-trimoxazole Diagnostic studies for Co-trimoxazole Treatment of Co-trimoxazole
Continuing Medical Education (CME)
CME Programs on Co-trimoxazole
International
Co-trimoxazole en Espanol Co-trimoxazole en Francais
Business
Co-trimoxazole in the Marketplace Patents on Co-trimoxazole
Experimental / Informatics
List of terms related to Co-trimoxazole

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Co-trimoxazole (abbreviated SXT, TMP-SMX, or TMP-sulfa) is an antibiotic combination of trimethoprim and sulfamethoxazole, in the ratio of 1 to 5, used in the treatment of a variety of bacterial infections. The name co-trimoxazole is the British Approved Name, and has been marketed worldwide under many trade names including Septrin (GSK), Bactrim (Roche), and various generic preparations. According to the American Hospital Formulary Service, "co-trimoxazole usually is bactericidal." Other sources list this antibiotic as bacteriostatic.

Synergistic action

Co-trimoxazole exhibits a theoretical, although perhaps not a clinical, synergistic antibacterial effect when compared to each of its components administered singly. This is because trimethoprim and sulfamethoxazole inhibit successive steps in the folate synthesis pathway (see diagram below). They did not exhibit synergistic effects, due to the requirement of a 1 in 5 ratio, which was observed in the laboratory. However, in clinical situations the ratio in the tissue was observed to be 1 in 20, resulting in no synergy.

File:THFsynthesispathway.png

Sulfamethoxazole acts as a false-substrate inhibitor of dihydropteroate synthetase. Sulfonamides such as sulfamethoxazole are analogues of p-aminobenzoic acid (PABA) and are competitive inhibitors of the enzyme; inhibiting the production of dihydropteroic acid.

Trimethoprim acts by interfering with the action of bacterial dihydrofolate reductase, inhibiting synthesis of tetrahydrofolic acid.

Folic acid is an essential precursor in the de novo synthesis of the DNA nucleosides thymidine and uridine. Bacteria are unable to take up folic acid from the environment (i.e. the infection host) thus are dependent on their own de novo synthesis - inhibition of the enzyme starves the bacteria of two bases necessary for DNA replication and transcription.

Clinical indications

Co-trimoxazole was claimed to be more effective than either of its components individually in treating bacterial infections, although this was later disputed. Along with its associated greater incidence of adverse effects including allergic responses (see below), its widespread use has been restricted in many countries to very specific circumstances where its improved efficacy is demonstrated. It may be effective in a variety of upper and lower respiratory tract infections, renal and urinary tract infections, gastrointestinal tract infections, skin and wound infections, septicaemias and other infections caused by sensitive organisms.

Specific indications for its use include: (Rossi, 2004)

• treatment and prophylaxis of pneumonia caused by Pneumocystis jirovecii (formerly identified as P. carinii) (Commmonly seen in immunocompromised patients including those suffering from HIV/AIDS)
• infections caused by Listeria monocytogenes, Nocardia spp., Stenotrophomonas maltophilia (Zanthomonas maltophilia)
• melioidosis
• shigellosis
• traveller's diarrhoea
• prophylaxis of cerebral toxoplasmosis in HIV patients
• Whipple's disease

Safety

There has been some concern about its use, however, since it has been associated with both frequent mild allergic reactions and serious adverse effects including Stevens-Johnson syndrome, myelosuppression, mydriasis, agranulocytosis, as well as severe liver damage (cholostatic hepatosis, hepatitis, liver necrosis, fulminant liver failure) and renal impairment up to acute renal failure and anuria. These side-effects are seen especially in the elderly and may be fatal. (Joint Formulary Committee, 2004). The folic acid is likely not the best option for the treatment of some adverse effects with associated with TMP-SMX, a better treatment is probably administration of folinic acid

In some countries, co-trimoxazole has been withdrawn due to these toxic effects.

Thus the current British Committee on Safety of Medicines (CSM) guidelines recommend limiting its use to:

• Pneumocystis pneumonia
• Toxoplasmosis and nocardiosis
• acute exacerbations of chronic bronchitis and infections of the urinary tract where there is good rationale for use
• acute otitis media in children where there is good rationale

References

• Rossi S, editor. Australian Medicines Handbook 2004. Adelaide: Australian Medicines Handbook; 2004. ISBN 0-9578521-4-2.
• British National Formulary, 51st edition (April 20, 2006). London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2006. ISBN 0853696683
• briandeer.com Newspaper campaign over adverse events; 1994-